Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Gilead’s multiple bets on fast Car production
A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.
FDA green and red lights: June 2024
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
FDA knocks back Regeneron’s CD20 T-cell engager
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.
AbbVie begins its Steap1 climb
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Adicet pivots
After disappointments in aggressive lymphomas Adicet focuses ADI-001 development on mantle cell lymphoma and goes into lupus.
